Neervous investors slash 32% off QLT; Revenue warning send shares falling

Article Abstract:

Shares of QLT Inc. tumbled $20.05 (Canadian) on the Toronto stock Exchange to $41.95. The Vancouver-based pharmaceutical company had announced that sales of its photodynamic therapy, Visudyne would be between $36 million (U.S.) and $38 million instead of the anticipated $40 million.

Statistical Data Included

---

QLT weathers stormy selloff

Article Abstract:

After a shaky period in the market drug company QLT Inc. stabalizes and looks to a strong future as concerns over the reimbursment issues for its Visudyne drug are resolved.

United States, Pharmaceutical Preparations, Drugs, Visudyne (Medication)

---

QLT profit jumps in third quarter

Article Abstract:

QLT Inc. turns third quarter profit. Company officials credits new eye drug with nearly tripling profits in the third quarter as Sun Life Financial takes in a small 6 percent profit, Canada Life Financial warns of losses.

Life Insurance, Direct Life Insurance Carriers, Executive changes & profiles, Insurance industry, Life insurance industry, Company Profile, Canada Life Financial Corp., Sun Life Financial Services of Canada Inc., QLTI

Similar abstracts:

• Abstracts: Certicom, Entrust slash 30% of work forces, alter strategies. Zenastra aims to outgrow Ottawa's high-tech gorillas
• Abstracts: Cominco cashes in on demand for power with electricity sale. Cominco merger `logical,' Teck CEO says
• Abstracts: TIW (Telesystem International Wireless Inc.) to finance British unit. Telesystems beats IPO target in bid to prop up British unit

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.